PCVX - CIK 0001649094
The table below shows Vaxcyte, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $312.78M | $209.93M | $194.18M | $148.13M | $116.94M | $131.51M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $33.07M |
| $32.45M |
| $32.04M |
| $32.66M |
| $22.99M |
| $21.47M |
| Operating income | -$345.85M | -$242.38M | -$226.22M | -$180.79M | -$139.92M | -$152.98M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$320.62M | -$212.83M | -$166.57M | -$140.72M | -$103.12M | -$128.70M |
| EPS (diluted) | -$2.30 | -$1.56 | -$1.22 | -$1.04 | -$0.83 | -$1.10 |